


20 June 2024

ROMEO D. LUMAGUI, JR.
Commissioner
Bureau of Internal Revenue
Quezon City



SUBJECT: Endorsement of the Updates to the List of VAT-Exempt Products under Republic Act Nos. 10963 and 11534

Dear Commissioner Lumagui:

With reference to the implementing guidelines on the Value-Added Tax (VAT) Exemption on medicines provided under Joint Administrative Order (JAO) No. 2-2018 dated 21 December 2018 and JAO No. 2021 -0001 dated 23 June 2021, may we provide you with the updates to the "List of VAT-Exempt Medicines for Hypertension, Cancer, Mental Illnesses, Tuberculosis, Kidney Diseases, Diabetes, and High Cholesterol". Listed hereunder are the updates as of 13 May 2024, effective upon the issuance of an FDA Advisory.

I. Inclusion

A. Medicines for Cancer

Generic Name	Dosage Strength	Dosage Form
Avelumab	200 mg/ 10 mL (20 mg/mL)	Concentrate for Solution for Infusion (IV)
Acalabrutinib	100 mg	Capsule
Olaparib	100 mg	Film-Coated Tablet
Olaparib	150 mg	Film-Coated Tablet
Trastuzumab	440 mg	Lyophilized Powder for Solution for Infusion (IV)
Trastuzumab	150 mg	Lyophilized Powder for Solution for Infusion (IV)
Trastuzumab deruxtecan	100 mg	Powder for Concentrate for Solution for Infusion (IV)

B. Medicines for High Cholesterol

Generic Name	Dosage Strength	Dosage Form
Rosuvastatin (as Calcium)	10 mg	Tablet



C. Medicines for Hypertension

Generic Name	Dosage Strength	Dosage Form
Olmesartan medoxomil	10 mg	Film-Coated Tablet
Perindopril (as arginine)	5 mg	Film-Coated Tablet
Perindopril (as arginine)	10 mg	Film-Coated Tablet
Indapamide + Amlodipine (as besilate)	1.5 mg/10 mg	Modified-Release Tablet
Indapamide + Amlodipine (as besilate)	1.5 mg/5mg	Modified-Release Tablet

D. Medicines for Mental Illness

Generic Name	Dosage Strength	Dosage Form
Sodium Valproate	200 mg/5 mL	Oral Solution
Valproic Acid	250 mg/5 mL	Syrup


II. Deletion

A. Medicines for Hypertension

Generic Name	Dosage Strength	Dosage Form
Trimetazidine	35 mg	Tablet
Trimetazidine Dihydrochloride	35 mg	Modified-Release Tablet
Trimetazidine Dihydrochloride	35 mg	Tablet
Trimetazidine Dihydrochloride	35 mg	Modified-Release Capsule
Trimetazidine Dihydrochloride	80 mg	Prolonged-Release Hard Capsule
Trimetazidine Hydrochloride	20 mg	Film-Coated Tablet
Trimetazidine Hydrochloride	35 mg	Modified Release Film-Coated Tablet
Trimetazidine Hydrochloride	35 mg	Modified Release Tablet
Trimetazidine Hydrochloride	60 mg	Sustained-Release Capsule

Justification: The approved indication of the drug products for delisting is intended for symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.

Should you have any question/clarifications, you may contact the FDA Policy and Planning Service via email at pps@fda.gov.ph.



[Signature]
DR. SAMUEL A. ZACATE
 Director General